相关实验视频
Updated: Jun 27, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
在多个患者群体中,JAK抑制剂的类固醇节约作用
Paola Conigliaro1, Clara Minerba1, Andrea Vendola1
1U.O.C. Reumatologia, Dipartimento di Medicina dei Sistemi, Universitá di Roma "Tor Vergata", Roma, Italy.
Frontiers in immunology
|April 29, 2024
概括
简氏激酶抑制剂 (JAK-i) 在风湿性关节炎和牛皮病性关节炎患者中有效降低口服葡萄糖皮质类药物 (OGC) 的剂量. 这种类固醇节约效应提供了显著的好处,减轻了长期的OGC副作用.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶抑制剂 (JAK-i) 是对类风湿性关节炎 (RA) 和牛皮性关节炎 (PsA) 的有效治疗方法.
- 口服葡萄皮质类药物 (OGC) 经常与JAK-i一起用于实现治疗目标.
- 由于其相关的不良影响,减少OGC至关重要.
研究的目的:
- 在现实环境中评估减少口服葡萄糖皮质体 (OGC) 剂量,治疗JAK抑制剂的活性RA和PsA患者.
- 评估JAK抑制剂对12个月的疾病活性和OGC剂量的影响.
主要方法:
- 一项前性研究招募了103名接受JAK-i治疗的患者 (88名RA,15名PsA).
- 被纳入的患者是生物素朴的,对bDMARDs反应不足,或难以治疗.
- 疾病活性和OGC剂量在基线和3,6和12个月后被记录下来.
主要成果:
- 在所有时间点中,在整个队列和在以前没有生物素的患者中观察到OGC剂量的显著降低.
- 没有足够的bDMARD反应的患者在3个月和12个月后显示OGC剂量减少.
- 疾病活动的改善和OGC撤销早在3个月就发生了,而不管之前的bDMARD治疗史.
结论:
- 雅克抑制剂在RA和PsA患者中表现出类固醇节约作用,使OGC剂量减少.
- 早期取消OGC是可以实现的,可能会减轻长期副作用.
- 对于需要长期治疗的患者来说,JAK-i的类固醇节约效益非常有价值.
更多相关视频
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
160
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
160
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
134
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
134
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
116
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
116
01:19Antiasthma Drugs: Leukotriene Modifiers
281
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
281
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
57
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
57